Skip to content

Study · Animal study (in vivo) · rabbit · 1984

3 results

Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.

Richards DB, Lipton JM

Peptides1 Jul 1984Cited by 46 (Europe PMC)

PMID6333677 (opens in a new tab)DOI10.1016/0196-9781(84)90027-5 (opens in a new tab)PepBankPUB-06333677
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In febrile rabbits, centrally administered lysine-proline-valine reduced fever.

    In plain wordsIn rabbits with fever, KPV given into the brain lowered fever.

    Peptide
    KPV
    Outcome
    DecreaseFever reduction after central administration
    Study

    rabbitn: not reported in source

    rabbits febrile after IV leukocytic pyrogen
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    0.5-2.0 mg · centralAs given in this study (rabbit).

    Source sentences

    Summary
    The tripeptide reduced fever after both central (0.5-2.0 mg)
    1 context sentence
    Summary · context
    The idea that the 11-13 amino acid sequence is important to the effect of the parent molecule was tested by giving lysine-proline-valine both centrally and peripherally to rabbits made febrile by IV administration of leukocytic pyrogen.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In febrile rabbits, peripherally administered lysine-proline-valine reduced fever.

    In plain wordsIn rabbits with fever, KPV given outside the brain lowered fever.

    Peptide
    KPV
    Outcome
    DecreaseFever reduction after peripheral administration
    Study

    rabbitn: not reported in source

    rabbits febrile after IV leukocytic pyrogen
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    2-200 mg · peripheralAs given in this study (rabbit).

    Source sentences

    Summary
    The tripeptide reduced fever after both central (0.5-2.0 mg) and peripheral (2-200 mg) administration.
    1 context sentence
    Summary · context
    The idea that the 11-13 amino acid sequence is important to the effect of the parent molecule was tested by giving lysine-proline-valine both centrally and peripherally to rabbits made febrile by IV administration of leukocytic pyrogen.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In febrile rabbits, lysine-proline-valine had lower potency than the parent molecule alpha-MSH (1-13).

    In plain wordsIn rabbits, KPV lowered fever less strongly than the full alpha-MSH molecule.

    Peptide
    KPV
    Outcome
    DecreaseAntipyretic potency relative to alpha-MSH (1-13)
    Study

    rabbitn: not reported in source

    rabbits febrile after IV leukocytic pyrogen
    Comparator
    alpha-MSH (1-13)
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    Dose not stated · central and peripheralAs given in this study (rabbit).

    Source sentences

    Summary
    the lower potency relative to that of the parent molecule suggests that other portions of the molecule are essential to full expression of the antipyretic effect.
    1 context sentence
    Summary · context
    The idea that the 11-13 amino acid sequence is important to the effect of the parent molecule was tested by giving lysine-proline-valine both centrally and peripherally to rabbits made febrile by IV administration of leukocytic pyrogen.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.